SCHEMBL564216

SCHEMBL564216

CC[C@@H](C(N)=O)N1CC(c2ccccc2)CC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
TP53 P04637 1/20 0.45
LMNA P02545 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10239542 1.00 BRD4 (0.50) BRD4MEN1KMT2AALDH1A1HPGD
SCHEMBL16061950 0.92 BRD4 (0.54) BRD4MEN1KMT2AALDH1A1HPGD
SCHEMBL662500 0.92 BRD4 (0.54) BRD4MEN1KMT2AALDH1A1HPGD
SCHEMBL662173 0.90 LMNA (0.49) BRD4MEN1KMT2AALDH1A1HPGD
SCHEMBL563943 0.88 LMNA (0.43) BRD4MEN1KMT2AALDH1A1LMNA
SCHEMBL563778 0.88 LMNA (0.43) BRD4MEN1KMT2ALMNACA12
SCHEMBL564124 0.87 LMNA (0.43) BRD4ALDH1A1TP53LMNACA12
SCHEMBL661084 0.87 SRD5A1 (0.52) BRD4MEN1KMT2AALDH1A1LMNA
SCHEMBL563294 0.86 LMNA (0.40) BRD4MEN1KMT2AALDH1A1HPGD
SCHEMBL563451 0.86 LMNA (0.40) BRD4MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265862-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB SA (BE) 2005-09-21 EP claimed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
EP-3260118-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2021-03-24 EP disclosed
CN-1740150-A 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB SA (BE) 2006-03-01 CN disclosed
CN-1740151-A 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB SA (BE) 2006-03-01 CN disclosed
CN-1680314-A 2-oxo-1-pyrrolidine derivatives, preparation method and use thereof UCB FARCHIM S A AG LTD (BE) 2005-10-12 CN disclosed
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses DIFFERDING EDMOND (BE) 2005-08-04 US disclosed
CN-1208319-C 2-oxo-1-pyrrolidine derivatives, preparation method and use thereof UCB SA (BE) 2005-06-29 CN disclosed
US-6911461-B2 For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse UCB, S.A. (BE) 2005-06-28 US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 US disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US disclosed
CN-1404469-A 2-oxo-1-pyrrolidine derivatives, preparation method and use thereof UCB SA (BE) 2003-03-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 BRD4 2140/4885MEN1 1354/4885KMT2A 1072/4885
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 BRD4 2991/4885MEN1 3878/4885KMT2A 140/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A BRD4 2553/4885MEN1 4306/4885KMT2A 530/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 BRD4 905/4885MEN1 4554/4885KMT2A 116/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 BRD4 905/4885MEN1 4554/4885KMT2A 116/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 BRD4 2991/4885MEN1 3878/4885KMT2A 140/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE BRD4 3982/4885MEN1 4285/4885KMT2A 793/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 BRD4 3450/4885MEN1 3438/4885KMT2A 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.